IV vs. shot vedolizumab for IBD with remote check-ins
Part of Digestive system clinical trials.
This study compares two ways of taking the IBD medicine vedolizumab (injecting under the skin versus through an IV line). You'll use a smartphone app to report your symptoms, so you can participate from home and help doctors learn which option works better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have a confirmed diagnosis of inflammatory bowel disease (IBD) like Crohn's or ulcerative colitis.
- You must be starting treatment with vedolizumab (Entyvio).
- You need a smartphone (iPhone 7 or newer, or Android from 2012 or later) with internet or Wi-Fi.
- You should be able to read and speak English or Spanish.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a weekly/regular skin injection version of vedolizumab can help adults with moderate to severe ulcerative colitis or Crohn’s disease who did not fully respond to other treatments or TNF blockers. It may help by moving you from an intravenous (IV) infusion to a self/clinic injection option.
This study tests the drug vedolizumab in adults with moderate to severe ulcerative colitis or Crohn's disease. It aims to see how well the medicine works in a community (non-hospital) setting.
This trial tests whether a personalized dosing method (using your own drug levels) can help people with Crohn's or ulcerative colitis maintain better control with vedolizumab or ustekinumab. It aims to see if adjusting doses based on your individual needs leads to fewer flare-ups and better outcomes.
This trial tests if regular video check-ins via phone or computer can help people with IBD stick to their medications and feel better emotionally. You would use a messaging app and video calls to stay in touch with your care team from home.
This trial tests vedolizumab, a biologic medicine that reduces inflammation, in children and teenagers who have moderate to severe ulcerative colitis or Crohn's disease and have not responded well to other treatments.
This study is for children and teenagers with ulcerative colitis or Crohn's disease who have already completed a previous vedolizumab study and are doing well. It will look at the long-term safety and effectiveness of continuing vedolizumab treatment.
Hear when a new Crohn's Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.